Lakeshore Biopharma Receives Revised Proposal To Acquire Company
LakeShore Biopharma Co., Ltd (LSB) on Thursday announced that its board of directors has received a revised preliminary non-binding proposal letter from a consortium to acquire all of the outstanding ordinary shares of the company in an all-cash transaction for $0.86 per ordinary share.
The consortium is comprised of Oceanpine Investment Fund II LP, Oceanpine Capital Inc., and Crystal Peak Investment Inc.
The revised proposal letter, dated August 26, revises the preliminary non-binding proposal letter dated August 18, previously received from Oceanpine Capital.
Get updates to this developing story <directly on Stocktwits.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Most popular stories
Market Research

- United States Lubricants Market Growth Opportunities & Share Dynamics 20252033
- UK Digital Health Market To Reach USD 37.6 Billion By 2033
- Immigration Consultancy Business Plan 2025: What You Need To Get Started
- United States Animal Health Market Size, Industry Trends, Share, Growth And Report 2025-2033
- Latin America Mobile Payment Market To Hit USD 1,688.0 Billion By 2033
- United States Jewelry Market Forecast On Growth & Demand Drivers 20252033
Comments
No comment